image
AtriCure, Inc. ATRC
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
Watchlist
$ 31.59
0.894 %
$ 1.54 B
Market Cap
-33.25
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ATRC stock under the worst case scenario is HIDDEN Compared to the current market price of 31.6 USD, AtriCure, Inc. is HIDDEN

ATRC Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ATRC stock under the base case scenario is HIDDEN Compared to the current market price of 31.6 USD, AtriCure, Inc. is HIDDEN

ATRC Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ATRC stock under the best case scenario is HIDDEN Compared to the current market price of 31.6 USD, AtriCure, Inc. is HIDDEN

ATRC Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ATRC

image
1M -6%
6M 11%
1Y 36%
3Y -84%
5Y -26%
All
$44.0$44.0$42.0$42.0$40.0$40.0$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
465 M REVENUE
16.55%
Growth Rates
1Year 16.55%
3Years 19.26%
5Years 15.05%
7Years 15.02%
10Years 15.78%
-40 M OPERATING INCOME
-49.96%
Growth Rates
1Year -49.96%
3Years 5.42%
5Years -3.85%
7Years -6.96%
10Years -9.36%
-44.7 M NET INCOME
100.00%
Growth Rates
1Year 100.00%
3Years 0.00%
5Years 14.87%
7Years 10.41%
10Years 7.18%
12.2 M OPERATING CASH FLOW
172.17%
Growth Rates
1Year 172.17%
3Years 42.37%
5Years 22.62%
7Years 18.93%
10Years 9.88%
30.2 M INVESTING CASH FLOW
38.58%
Growth Rates
1Year 38.58%
3Years 8.76%
5Years 74.29%
7Years 34.68%
10Years 11.56%
-3.6 M FINANCING CASH FLOW
-11159.38%
Growth Rates
1Year -11159.38%
3Years 22.17%
5Years -4.58%
7Years -12.67%
10Years -0.53%
124 M REVENUE
7.22%
Growth Rates
1Year 16.55%
3Years 19.26%
5Years 15.05%
7Years 15.02%
10Years 15.78%
-14.5 M OPERATING INCOME
-96.12%
Growth Rates
1Year -49.96%
3Years 5.42%
5Years -3.85%
7Years -6.96%
10Years -9.36%
-15.6 M NET INCOME
-98.24%
Growth Rates
1Year 100.00%
3Years 0.00%
5Years 14.87%
7Years 10.41%
10Years 7.18%
5.84 M OPERATING CASH FLOW
-70.83%
Growth Rates
1Year 172.17%
3Years 42.37%
5Years 22.62%
7Years 18.93%
10Years 9.88%
-14.7 M INVESTING CASH FLOW
-334.54%
Growth Rates
1Year 38.58%
3Years 8.76%
5Years 74.29%
7Years 34.68%
10Years 11.56%
1.74 M FINANCING CASH FLOW
621.92%
Growth Rates
1Year -11159.38%
3Years 22.17%
5Years -4.58%
7Years -12.67%
10Years -0.53%
Balance Sheet AtriCure, Inc.
image
Current Assets 268 M
Cash & Short-Term Investments 123 M
Receivables 60.3 M
Other Current Assets 84.8 M
Non-Current Assets 342 M
Long-Term Investments 0
PP&E 47.4 M
Other Non-Current Assets 294 M
20.14 %9.90 %13.91 %7.78 %48.27 %Total Assets$609.3m
Current Liabilities 73.4 M
Accounts Payable 25 M
Short-Term Debt 2.8 M
Other Current Liabilities 45.6 M
Non-Current Liabilities 74.9 M
Long-Term Debt 73.7 M
Other Non-Current Liabilities 1.21 M
16.87 %30.73 %49.69 %Total Liabilities$148.4m
EFFICIENCY
Earnings Waterfall AtriCure, Inc.
image
Revenue 465 M
Cost Of Revenue 118 M
Gross Profit 348 M
Operating Expenses 388 M
Operating Income -40 M
Other Expenses 4.68 M
Net Income -44.7 M
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)465m(118m)348m(388m)(40m)(5m)(45m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
74.69% GROSS MARGIN
74.69%
Averages
1Year 74.69%
3Years 74.79%
5Years 74.34%
7Years 74.07%
10Years 73.39%
-8.60% OPERATING MARGIN
-8.60%
Averages
1Year -8.60%
3Years -9.40%
5Years -13.37%
7Years -12.81%
10Years -14.47%
-9.61% NET MARGIN
-9.61%
Averages
1Year -9.61%
3Years -10.43%
5Years -7.26%
7Years -8.86%
10Years -11.99%
-9.70% ROE
-9.70%
Averages
1Year -9.70%
3Years -8.80%
5Years -5.54%
7Years -7.20%
10Years -10.15%
-7.34% ROA
-7.34%
Averages
1Year -7.34%
3Years -6.74%
5Years -3.76%
7Years -4.43%
10Years -6.31%
-7.60% ROIC
-7.60%
Averages
1Year -7.60%
3Years -6.91%
5Years -7.15%
7Years -6.81%
10Years -8.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AtriCure, Inc.
image
20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -44.7 M
Depreciation & Amortization 18.7 M
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital 0
Others 12.2 M
Free Cash Flow 12.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AtriCure, Inc.
image
Wall Street analysts predict an average 1-year price target for ATRC of $41.5 , with forecasts ranging from a low of $26 to a high of $58 .
ATRC Lowest Price Target Wall Street Target
26 USD -17.70%
ATRC Average Price Target Wall Street Target
41.5 USD 31.37%
ATRC Highest Price Target Wall Street Target
58 USD 83.60%
Price
Max Price Target
Min Price Target
Average Price Target
6060555550504545404035353030252520201515May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership AtriCure, Inc.
image
Sold
0-3 MONTHS
233 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
84.2 K USD 1
9-12 MONTHS
36.1 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
111 K USD 1
9-12 MONTHS
7. News
AtriCure to Host Analyst & Investor Day on March 26, 2025 MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expa. businesswire.com - 1 month ago
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2 months ago
AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes. seekingalpha.com - 2 months ago
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 2 months ago
AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates AtriCure (ATRC) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.21 per share a year ago. zacks.com - 2 months ago
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. “2024 was another outstanding year at AtriCure, marked by continued progress on driving growth, improving profitability, and the introduction of several meaningful product launches across our key fran. businesswire.com - 2 months ago
Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS Besides Wall Street's top -and-bottom-line estimates for AtriCure (ATRC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. zacks.com - 2 months ago
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 fin. businesswire.com - 2 months ago
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio. businesswire.com - 3 months ago
AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 5 months ago
AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 5 months ago
8. Profile Summary

AtriCure, Inc. ATRC

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 1.54 B
Dividend Yield 0.00%
Description AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Contact 7555 Innovation Way, Mason, OH, 45040 https://www.atricure.com
IPO Date Aug. 5, 2005
Employees 1300
Officers Mr. Justin J. Noznesky Chief Marketing & Strategy Officer Mr. Michael H. Carrel Chief Executive Officer, President & Director Ms. Deborah Yount Chief Human Resources Officer Mr. Karl S. Dahlquist CCEP, J.D. Chief Legal Officer Mr. Douglas J. Seith Chief Operating Officer Mr. Salvatore Privitera J.D. Chief Technical Officer Ms. Angela L. Wirick Chief Financial Officer Dr. Vinayak Doraiswamy Ph.D. Chief Scientific Officer Valerie Storch-Willhaus Vice President of Corporate Marketing & Communications